2015 Biopharma Healthcare Provider Leads 
Impetus Digital
MARCH 15, 2024
Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017).
PM360
AUGUST 24, 2023
Today’s workforce includes Traditionalists (born 1927-1945), Boomers (1946-1964), Gen X (1965-1980), Millennials (1981-1996), and Gen Z (1997-2015). Marketing and comms teams that go beyond simply accepting generational differences by leveraging them proactively will lead to increased engagement, innovation, and organizational success.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PM360
AUGUST 9, 2022
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. Then between 2005-2015, there were 110 global blockbuster launches, with a high concentration in specialty care and biologics. In oncology, it’s 47% less.
Clarivate
APRIL 24, 2023
These developments, together with Walgreens’ recent rollout of Health Corners that help patients manage chronic conditions and its October 2022 announcement that it would fully acquire CareCentrix (a platform that coordinates post-acute and home care), underscore Walgreens’ plans to become a leading healthcare provider.
European Pharmaceutical Review
DECEMBER 21, 2022
Furthermore, entire value chains must be redesigned and the CO 2 emitters (especially point source emitters), chemical industry and power sector, downstream users, eg, healthcare industries and their customers, and healthcare providers need to be coordinated, informed, sensitised and must work out contractual frameworks to de-risk the investments.
Expert insights. Personalized for you.
83 
Let's personalize your content